TUG1 and cancer: Because immune checkpoint inhibitors (ICI) are used for the treatment of heavily mutated cancers with MSI-H80, it might be an attractive treatment strategy to combine them with TUG1 ASO, even for cancers where the MSI-H molecular phenotype is uncommon.